Xanthine oxidase inhibitor in Duchenne muscular dystrophy.
The treatment with xanthine oxidase inhibitor, allopurinol, was evaluated in 17 patients with Duchenne muscular dystrophy (aged 2 years 9 months to 13 years 9 months) using the double blind technique. The total observed period was 27 months. The results of 100-point scale of graded functional abilities revealed that an improvement, unchange and progression of dysfunction were found in 2, 2 and 6 patients, respectively, in allopurinol group and in 0, 2 and 5 patients, respectively in placebo group. The patients' age and stage of the disease seemed to be related to the effectiveness or allopurinol treatment.
D000255:Adenosine Triphosphate / Q000378:metabolism; D000293:Adolescent; D000493:Allopurinol / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003402:Creatine Kinase / Q000097:blood; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D009132:Muscles / Q000378:metabolism; D009136:Muscular Dystrophies / Q000188:drug therapy* / Q000201:enzymology; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors*
D000493:Allopurinol; D000255:Adenosine Triphosphate; D014969:Xanthine Oxidase; D001219:Aspartate Aminotransferases; D003402:Creatine Kinase